News headlines about Evolent Health (NYSE:EVH) have trended positive recently, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Evolent Health earned a media sentiment score of 0.33 on AlphaOne’s scale. AlphaOne also assigned news coverage about the technology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Alpha One’s scoring:
- Analysts Expect Evolent Health, Inc (EVH) Will Post Quarterly Sales of $104.54 Million (americanbankingnews.com)
- Official Price Target Objectives For Evolent Health, Inc. (EVH), AmTrust Financial Services, Inc. (AFSI) – StockNewsMagazine (stocknewsmagazine.com)
- Volume Moving the Tape For Evolent Health Inc (EVH) – Evergreen Caller (evergreencaller.com)
- Evolent Health, Inc (EVH) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- -$0.13 Earnings Per Share Expected for Evolent Health, Inc (EVH) This Quarter (americanbankingnews.com)
Shares of Evolent Health (NYSE EVH) traded up 5.18% during trading on Friday, hitting $26.40. 1,387,488 shares of the stock were exchanged. Evolent Health has a 1-year low of $14.50 and a 1-year high of $27.50. The firm’s 50-day moving average is $24.43 and its 200 day moving average is $20.48. The company’s market cap is $1.52 billion.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $104.38 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. The company’s revenue for the quarter was up 116.2% compared to the same quarter last year. Equities analysts forecast that Evolent Health will post ($0.41) earnings per share for the current fiscal year.
Several analysts recently issued reports on the stock. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Wednesday, May 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a report on Thursday, April 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price objective on shares of Evolent Health in a report on Wednesday, March 1st. Leerink Swann set a $24.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a report on Tuesday, February 28th. Finally, TheStreet upgraded shares of Evolent Health from a “d” rating to a “c-” rating in a research note on Monday, May 22nd. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Evolent Health presently has an average rating of “Buy” and a consensus price target of $28.40.
TRADEMARK VIOLATION WARNING: “Evolent Health (EVH) Earns Daily Media Sentiment Score of 0.33” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/06/17/evolent-health-evh-getting-favorable-media-coverage-report-shows-updated.html.
In other Evolent Health news, major shareholder Upmc sold 2,690,961 shares of the business’s stock in a transaction on Friday, March 31st. The stock was sold at an average price of $19.53, for a total value of $52,554,468.33. Following the sale, the insider now directly owns 9,171,260 shares of the company’s stock, valued at $179,114,707.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Nicholas Mcgrane sold 1,667 shares of the company’s stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $22.52, for a total value of $37,540.84. Following the completion of the sale, the chief financial officer now owns 132,047 shares of the company’s stock, valued at approximately $2,973,698.44. The disclosure for this sale can be found here. Insiders have sold 11,104,090 shares of company stock worth $244,902,211 over the last 90 days. 8.79% of the stock is currently owned by corporate insiders.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.